Westfield Capital Management
CBAY

Westfield Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Westfield Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-700,056
Closed -$16.5M – 268
2023
Q4 		$16.5M Buy
+700,056
New +$12.5M 0.1% 183
2019
Q2 		– Sell
-834,330
Closed -$11.1M – 274
2019
Q1 		$11.1M Sell
834,330
-241,885
-22% -$2.57M 0.08% 195
2018
Q4 		$8.47M Buy
1,076,215
+166,835
+18% +$1.59M 0.07% 194
2018
Q3 		$10.1M Sell
909,380
-5,840
-0.6% -$72.5K 0.07% 203
2018
Q2 		$12.3M Buy
+915,220
New +$11.5M 0.09% 202

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Westfield Capital Management's CBAY Position: Q1 2024 in Review

Westfield Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 700,056 shares — an estimated $16.5M sold.

Westfield Capital Management first reported a position in CBAY in Q2 2018 and held it in 5 quarters. The position peaked at $16.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Westfield Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Westfield Capital Management sold 700,056 Cymabay Therapeutics shares in Q1 2024, an estimated $16.5M.
  • Westfield Capital Management first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 5 quarters.
  • Westfield Capital Management's Cymabay Therapeutics position peaked at $16.5M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Westfield Capital Management's 13F filing for Q1 2024, filed 10 May 2024.